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Endoscopic radiofrequency ablation combined with endoscopic resection
for early neoplasia in Barrett’s esophagus longer than 10 cm
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Paul Fockens, MD, PhD, Bas L.A.M. Weusten, MD, PhD, Jaques J.G.H.M. Bergman, MD, PhD
Amsterdam, Nieuwegein, The Netherlands
Background: Radiofrequency ablation (RFA) is safe and effective for eradicating Barrett’s esophagus (BE) and
BE-associated early neoplasia. Most RFA studies have limited the baseline length of BE (10 cm), and therefore
little is known about RFA for longer BE.
Objective: To assess the safety and efficacy of RFA with or without prior endoscopic resection (ER) for BE 10
cm containing neoplasia.
Design: Prospective trial.
Setting: Two tertiary-care centers.
Patients: This study involved consecutive patients with BE 10 cm with early neoplasia.
Intervention: Focal ER for visible abnormalities, followed by a maximum of 2 circumferential and 3 focal RFA
procedures every 2 to 3 months until complete remission.
Main Outcome Measurements: Complete remission, defined as endoscopic resolution of BE and no intestinal
metaplasia (CR-IM) or neoplasia (CR-neoplasia) in biopsy specimens.
Results: Of the 26 patients included, 18 underwent ER for visible abnormalities before RFA. The ER specimens
showed early cancer in 11, high-grade intraepithelial neoplasia (HGIN) in 6, and low-grade intraepithelial neoplasia
(LGIN) in 1. The worst residual histology, before RFA and after any ER, was HGIN in 16 patients and LGIN in 10 patients.
CR-neoplasia and CR-IM were achieved in 83% (95% confidence interval [CI], 63%-95%) and 79% (95% CI, 58%-93%),
respectively. None of the patients had fatal or severe complications and 15% (95% CI, 4%-35%) had moderate complications.
During a mean ( standard deviation) follow-up of 29 ( 9.1) months, no neoplasia recurred.
Limitations: Tertiary-care center, short follow-up.
Conclusion: ER for visible abnormalities, followed by RFA of residual BE is a safe and effective treatment for BE
10 cm containing neoplasia, with a low chance of recurrence of neoplasia or BE during follow-up. (Gastrointest
Endosc 2011;73:682-90.)Abbreviations: APC, argon plasma coagulation; BE, Barrett’s esophagus;
CI, confidence interval; CR-IM, complete removal of intestinal metapla-
sia; CR-neoplasia, complete removal of neoplasia; EC, early cancer; ER,
endoscopic resection; HGIN, high-grade intraepithelial neoplasia; IM,
intestinal metaplasia; IQR, interquartile range; LGIN, low-grade intra-
epithelial neoplasia; RFA, radiofrequency ablation.
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Herrero et al Endoscopic radiofrequency ablation in Barrett’s esophagusBarrett’s esophagus (BE) is a premalignant condition char-
acterized by the presence of a columnar-lined distal esoph-
agus containing intestinal metaplasia (IM) on biopsy.1 BE is
aused by chronic gastroesophageal reflux and is found in
% of patients undergoing endoscopy for reflux symptoms.2
BE can undergo a multiple-step transition from low-grade
intraepithelial neoplasia (LGIN) to high-grade intraepithelial
neoplasia (HGIN) to invasive adenocarcinoma.3 HGIN and
mucosal cancer in BE have a low risk of lymph node metas-
tases and can therefore be treated endoscopically by endo-
scopic resection (ER) techniques, endoscopic ablative tech-
niques, or a combination thereof. ER techniques allow for
histological evaluation of the resected specimen, which is the
only reliable way to exclude patients with submucosal invad-
ing cancers from further endoscopic treatment.4 After focal
removal of endoscopically visible abnormalities, the remain-
ing BE generally contains residual HGIN or LGIN, and recur-
rences occur in 19% to 30% of cases.5-7 Therefore, ablation of
the remaining BE has been advocated, and recent studies
suggest that this reduces the chances of recurrent neoplasia
elsewhere in the BE during follow-up.7
Radiofrequency ablation (RFA) is one of the most prom-
ising ablative techniques for BE. The technique uses a bipolar
electrode that is available as a balloon-based device for pri-
mary circumferential ablation or as a cap-based device that
can be mounted on the tip of the endoscope for focal
ablation.
RFA has been proven to be safe and effective for the
removal of IM and neoplasia in BE in a wide range of clinical
studies, including two randomized trials.8-15 In addition, stud-
ies have shown that the regenerated neosquamous epithe-
lium after RFA is free of the oncogenetic abnormalities as
present in the BE before RFA and that subsquamous foci of
IM (buried BE) are rare.16 Furthermore, RFA preserves the
iameter, compliance, and motility of the esophagus and is
ssociated with a low rate of stenosis.17
From other endoscopic therapies, it is known that safety
and efficacy may depend on the length of the BE segments
treated: after radical mucosectomy and after photodynamic
therapy, stenosis rates, for example, increase with the BE
length treated.18,19 In addition, the rate of complete removal
f the whole BE segment is found to decrease with the length
f the BE.20 For these reasons, endoscopic therapy is thought
o be more difficult in longer BE segments. Most studies on
he use of ablation techniques for BE have therefore re-
tricted the baseline BE length to less than 10 cm.
The aim of this study, therefore, was to assess the safety
nd efficacy of RFA with or without prior ER for BE of10
m containing early neoplasia.
METHODS
Patient selection
Patients were consecutively included from January 2006
until November 2008. They were treated at two tertiary-
care referral centers in The Netherlands: the Academic d
www.giejournal.org Vedical Center in Amsterdam and the St. Antonius Hospi-
al in Nieuwegein. Patients were eligible if they met all the
ollowing inclusion criteria: age 18 years; maximum BE
ength 10 cm; presence of LGIN, HGIN, or early cancer
EC) (defined as  T1sm1 infiltration with good or mod-
rate differentiation and no lymphatic/vascular invasive
rowth) confirmed by a study pathologist (F.T.K., M.V.,
.S.) at two endoscopic procedures; no signs of metastasis
n EUS (in case of HGIN and EC) or CT scan (in case of
C). Patients were excluded if they had any of the follow-
ng exclusion criteria: previous treatment with photody-
amic therapy or argon plasma coagulation (APC); prior
R larger than 3 cm in length or extending over more than
0% of the circumference; ER specimen showing cancer at
he vertical (deep) resection margin, T1sm1 invasion,
oor tumor differentiation, or lymphatic/vascular invasive
rowth; persistent visible abnormalities after ER or inva-
ive cancer in mapping biopsies (post-ER) before RFA.
The current study enrolled some patients who were
ncluded in other published or ongoing trials from our
roup as well as patients who were treated outside of
hese trials, mainly because of the length of their BE (Table
). Patients who were not previously consented as part of
rior internal review board–approved trials provided in-
ormed consent for participation in this study.
ndoscopic work-up before RFA
Patients underwent two high-resolution endoscopies of
he BE with biopsies from all visible abnormalities (ie, any
odule, flat lesion, or mucosal irregularity, no matter how
ubtle) and random 4-quadrant biopsies every 2 cm. All
esions suspicious for EC were endoscopically resected,
or removal and staging of these lesions before RFA. ER
as performed with patients under conscious sedation as
n outpatient procedure either with the ER-cap technique
after submucosal lifting) or the multi-band mucosectomy
echnique. Depending on the size, lesions were resected
n bloc or in multiple pieces (piecemeal procedure). All
esected specimens were retrieved, pinned down on par-
ffin with the mucosal side up, and fixed in formalin for
istological evaluation. No attempts were made to recon-
truct the piecemeal resections.
After ER, the residual BE was mapped twice to exclude
esidual lesions and residual cancer in the flat mucosa.
he RFA system and endoscopic procedure
The RFA system and endoscopic procedure have been
Take-homeMessage
● Radiofrequency ablation preceded by endoscopic
resection for visible abnormalities, when present, is also a
safe and effective treatment for Barrett’s esophagus
longer than 10 cm in length containing neoplasia.escribed previously.9-12 In short, RFA procedures were
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Endoscopic radiofrequency ablation in Barrett’s esophagus Herrero et alperformed as outpatient procedures with patients under
conscious sedation with midazolam and fentanyl or pethi-
dine. Patients were discharged after 2 to 4 hours of
observation.
Circumferential RFA was performed with the balloon-
based HALO360 system (Bârrx Medical Inc, Sunnyvale,
alif). The BE was ablated at 12J/cm2 under endoscopic
control. Two ablation passes of the BE were performed,
with cleaning of the ablation after the first pass.
Focal RFA was performed with the cap-based HALO90
system (Bârrx) for treatment of residual BE after circum-
ferential RFA. Areas were ablated twice by using the
“double-double” 15J/cm2 regimen (ie, 2 ablation passes
onsisting of 2 consecutive ablations with 15J/cm2 each,
ith cleaning of the ablated area after the first pass),
hich is in accordance with our initial experience with
he focal ablation device and all of our published and
ngoing studies.9-12 In all focal RFA sessions, the area of
the neosquamocolumnar junction at the upper end of
the gastric folds was ablated, irrespective of its endo-
scopic appearance.
After each RFA procedure, patients were treated for a
period of 2 weeks with ranitidine 300 mg at bedtime and
5 mL sucralfate suspension (200 mg/mL) 4 times daily in
addition to the maintenance medication of esomeprazole
40 mg twice daily.
Treatment protocol and follow-up
In case of prior ER, the first circumferential RFA of the
whole BE segment was performed at least 6 weeks after
ER. Subsequent RFA sessions were scheduled every 2 to
3 months until complete eradication of all visible BE
was achieved. Patients underwent a maximum of 2
circumferential and 3 focal ablations. In case of residual
BE after the maximum number of RFA sessions, an ER
was performed as an “escape” procedure (Fig. 1). Once
complete remission of all visible BE was achieved, and
complete histological clearance of dysplasia and IM was
documented (or 2-3 months after the escape proce-
TABLE 1. Patients of current study participating in other trials
Study Design Baseline path
AMC-II9 Single-center, prospective study HGIN/EC
EURO-I12 Multicenter, prospective study HGIN/EC
EURO-II* Multicenter, prospective study HGIN/EC
SURF* Multicenter, randomized,
controlled trial
LGIN
None Prospective registration HGIN/EC
BE, Barrett’s esophagus; HGIN, high-grade intraepithelial neoplasia; EC, early c
*Ongoing trials.dure), patients were followed with high-resolution en- i
684 GASTROINTESTINAL ENDOSCOPY Volume 73, No. 4 : 2011oscopies with narrow-band imaging at 3, 6, and 12
onths and annually thereafter. At these follow-up en-
oscopies, 4-quadrant biopsy specimens were obtained
igure 1. Flow-chart of treatment protocol. EC, early cancer; HGIN, high-grade
ntraepithelial neoplasia; LGIN, low-grade intraepithelial neoplasia; BE, Barrett’s
sophagus; ER, endoscopic resection; HALO, HALO360 system, HALO90 system,
Bârrx Medical Inc, Sunnyvale, Calif); NBI, narrow-band imaging; Q, quadrant.
y BE inclusion length
No. of pts BE>10 cm included
in this study
2-10 cm 2
12 cm 8
12 cm 5
No restrictions 4
No restrictions 7
LGIN, low-grade intraepithelial neoplasia.olog
ancer;mmediately distal (5 mm) to the neosquamocolumnar
www.giejournal.org
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Herrero et al Endoscopic radiofrequency ablation in Barrett’s esophagusjunction and from the neosquamous epithelium at 2-cm
intervals.
Histology
All ER specimens and biopsy specimens were routinely
processed and stained with hematoxylin and eosin and
assessed by three study pathologists (F.T.K., M.V., C.S.).4
The ER specimens and biopsy specimens were evaluated
for the presence of neoplasia and cancer according to the
World Health Organization classification.21 In the case of
ancer in the ER specimens, tumor infiltration depth, tu-
or differentiation grade, the presence of lymphatic/
ascular invasive growth, and radicality of the vertical
esection margins were documented. Biopsy specimens of
he neosquamous epithelium were also evaluated for the
resence of subsquamous foci of IM.
Outcome parameters
Primary endpoints were (1) complete removal of neo-
plasia (CR-neoplasia), defined as the absence of LGIN,
HGIN, and EC from all biopsy specimens obtained during
the first follow-up endoscopy and (2) complete removal of
intestinal metaplasia (CR-IM), defined as endoscopic res-
olution of all BE and no evidence of IM in any of the
biopsy specimens obtained during the first follow-up en-
doscopy (including the biopsy specimens from the neos-
quamocolumnar junction and from the neosquamous
mucosa).
Secondary endpoints were (1) recurrence of neoplasia
during follow-up, (2) recurrence of BE during follow-up
(either endoscopic or histological), and (3) the complica-
tion rate of ER and RFA.
Severity of the complications was graded as follows:
mild (unplanned hospital admission, hospitalization 3
ays, clinically significant bleeding with a hemoglobin
rop of 3 g/dL and no need for transfusion); moderate
4-10 days’ hospitalization, 4 units blood transfusion,
eed for repeat endoscopic intervention, radiologic inter-
ention); severe (hospitalization 10 days, intensive care
nit admission, need for surgery, 4 units blood transfu-
ion. In the case of stenosis: 5 endoscopic dilatations,
tent placement, or incision therapy); or fatal (death attrib-
table to procedure 30 days or longer with continuous
ospitalization).22
Statistics
Statistical analysis was performed with a statistical soft-
ware package (Statistical Package for the Social Sciences
14.0.2; SPSS Inc, Chicago, Ill). Data with a normal distri-
bution were described with the mean and standard devi-
ation, whereas data with a skewed distribution were
described by the median and interquartile ranges (IQR)
or ranges. Confidence intervals (CI) of the proportions
were calculated with Confidence Interval Analysis, ver-
sion 1.0.23 R
www.giejournal.org VESULTS
atients
Between January 2006 and October 2008, 26 consecu-
ive patients (21 men, mean [ SD] age 66  10.6 years)
ere included in this study. Patient characteristics are
escribed in Table 2. Median BE length was C9M11 cm
IQR C8-10, M10-12). None of the patients showed signs of
ctive reflux disease, yet 13 patients (50%) were found to
ave reflux stenosis at the proximal end of the BE seg-
ent. These stenoses were generally asymptomatic and
llowed passage of the therapeutic endoscopes. In 3 pa-
ients, however, endoscopic bougienage of the reflux ste-
osis was required before treatment to facilitate the intro-
uction of an ER cap and RFA catheters.
Eighteen patients underwent ER of visible abnormalities
efore RFA. The ER cap technique was used in 5 patients
nd multi-band mucosectomy in 13 patients. The ER
pecimens showed early cancer in 11 patients (intramu-
osal [n  10], sm1 [n  1], all with good or moderate
ifferentiation and no lymphatic/vascular invasive
rowth), HGIN in 6 patients, and LGIN in 1 patient. Before
TABLE 2. Patient characteristics (n 26)
Characteristic
Age, mean ( SD), y 66 ( 10.6)
Sex, no.
Male 21
Female 5
BE length, mean (range) cm
C 9 (6-19)
M 11 (10-20)
Overall worst histology, no.
EC 11
HGIN 11
LGIN 4
ER before RFA, no.
Yes 18
No 8
Histology flat mucosa before RFA, no.
HGIN 16
LGIN 10
SD, Standard deviation; BE, Barrett’s esophagus; C, circumferential
extent;M,maximum extent; EC, early cancer; HGIN, high-grade
intraepithelial neoplasia; LGIN, low-grade intraepithelial neoplasia;
ER, endoscopic resection; RFA, radiofrequency ablation.FA, and after ER if applicable, all patients had flat mucosa
olume 73, No. 4 : 2011 GASTROINTESTINAL ENDOSCOPY 685
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Endoscopic radiofrequency ablation in Barrett’s esophagus Herrero et alwithout visible abnormalities, with random mapping bi-
opsies showing HGIN in 16 and LGIN in 10 patients.
Primary outcomes: eradication of early
cancer, neoplasia, and intestinal metaplasia
In 2 patients (8%), the treatment protocol was discon-
tinued because of unrelated comorbidity (psychiatric dis-
order and lung cancer). In both, at the last endoscopy
before discontinuation, endoscopic regression of BE was
99% without histological information available. These pa-
tients were excluded from analysis of the primary
endpoints.
CR-neoplasia was achieved in 20 of 24 patients: 83%
(95% CI, 63%-95%). CR-IM was achieved in 19 of 24 pa-
tients: 79% (95% CI, 58%-93%) (Figs. 2 and 3). In 4 patients
(15% [95% CI, 4%-35%]), the RFA treatment was discontin-
ued after 1 to 3 sessions because of poor healing and no or
almost no regeneration of neosquamous mucosa (Fig. 4).
These patients were therefore considered as failures for
the primary endpoints of the study (CR-neoplasia and
Figure 2. Enrollment and outcomes. ER, endoscopic resection; RFA,
eoplasia; LGIN, low-grade intraepithelial neoplasia; pts, patients; BE,
omplete removal of endoscopically visible BE and histological intestin
ollow-up.CR-IM). (
686 GASTROINTESTINAL ENDOSCOPY Volume 73, No. 4 : 2011Patients achieved CR-neoplasia and CR-IM after a me-
ian of one (IQR 1-2) circumferential and two (IQR 1-3)
ocal ablations. Three patients underwent an escape ER for
ersisting BE islands after the maximum number of RFA
reatments. Another two patients were treated with APC
fter RFA: in one patient for a small, persisting BE island
1  2 mm), which in the opinion of the endoscopist did
ot justify ER; in the other patient, APC was performed for
mall (5 mm), remaining BE islands after two circumfer-
ntial RFA sessions, because the focal RFA catheter could
ot pass the reflux stenosis despite dilatation.
Two patients underwent a diagnostic ER during the
reatment protocol of slightly elevated BE islands in order
o avoid having RFA performed on possibly invading can-
ers (thus not to supplement the efficacy of RFA). Histol-
gy of both ER specimens showed only LGIN.
econdary outcome: complications after ER
nd RFA
No fatal or severe complications occurred. Four patients
requency ablation; EC, early cancer; HGIN, high-grade intraepithelial
tt’s esophagus; CR-neoplasia, complete removal of neoplasia; CR-IM,
taplasia; APC, argon plasma coagulation; IM, intestinal metaplasia; FU,radiof
Barre
al me15% [95% CI, 4%-35%]) developed complications after ER
www.giejournal.org
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Herrero et al Endoscopic radiofrequency ablation in Barrett’s esophagusor RFA, which were graded as moderate. One patient
developed delayed bleeding 6 days after ER. This patient
received blood transfusion and was treated successfully
with endoscopic hemostatic therapy (adrenaline injection,
bipolar probe coagulation, and clip placement). Two pa-
Figure 3. Barrett’s esophagus (BE) with C7M10 length treated with en
emaining BE segment, resulting in complete eradication of neoplasia an
H, Complete removal of the whole BE segment after endoscopic rese
arrow-band imaging. C, circumferential extent (cm); M, maximum exte
Figure 4. Barrett’s esophagus (BE) with C10M11 length, treated with en
remaining BE segment. Radiofrequency ablation failed to remove the BE
E, and F, Three months after the first ablation the esophagus had not co
second circumferential ablation was performed at a later stage. G, H, and
As a consequence, ablations were stopped. C, circumferential extent (cmtients had unplanned admissions: one patient was admit- d
www.giejournal.org Ved for observation after a superficial laceration that
howed no transmural leakage on the swallowing contrast
xamination. However, this 80-year-old patient became
elirious and, as a result, the admission was prolonged;
nother patient was admitted 3 days after the RFA proce-
pic resection for mucosal cancer and radiofrequency ablation for the
stinal metaplasia. A, B, C, and D, BE before any treatment. E, F, G, and
and 3 ablation sessions. I, J, K, and L, Corresponding images with
).
pic resection for a mucosal cancer and radiofrequency ablation for the
ent. A, B, and C, BE after endoscopic resection and before ablation. D,
tely healed, with only limited regression into neosquamous mucosa. A
gain, no significant visible response was seen after the second ablation.
, maximum extent (cm).dosco
d inte
ctiondosco
segm
mple
I, Aure because of pain, nausea, and vomiting that resolved
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Endoscopic radiofrequency ablation in Barrett’s esophagus Herrero et alwith conservative treatment. Because both admissions
were for 4 days, these complications were graded as
moderate. The fourth patient with a moderate complica-
tion had a relative stenosis after ER and developed symp-
toms of dysphagia after RFA, which resolved after two
dilatations.
In 7 patients (27% [95% CI, 12%-48%]), a superficial
laceration was observed during the circumferential abla-
tion procedure. Six of these superficial lacerations re-
mained asymptomatic, did not require intervention, and
were therefore not considered to be complications. How-
ever, one patient was admitted for observation (see pre-
viously), because this was the first laceration we observed
during our RFA experience. This patient, again, did not
experience symptoms attributable to the laceration. Lacer-
ations were located either at the level of the reflux stenosis
(n  4) or at the level of the ER scar (n  3). In 4 of the
patients, the laceration was noted after the first circum-
erential ablation pass, and the second pass was either
herefore not performed (n  1) or was modified by the
se of a balloon with a smaller diameter (n  1) or by
kipping the zone containing the laceration during the
econd RFA pass (n  2). All patients were able to con-
inue the RFA according to the protocol 2 to 3 months
ater.
Secondary outcome: follow-up
Patients who achieved CR-neoplasia and CR-IM were
followed-up for a mean ( SD) duration of 29  9.1
months (21  11.7 months since last treatment session).
one of the 20 patients developed neoplasia during
ollow-up, thus 100% (95% CI, 82%-100%) continued to
ave CR-neoplasia status.
Two patients had small islands of BE during follow-up.
ne patient had a 3-mm island 6 months after treatment,
ocated at the upper part of the initial BE segment imme-
iately distal to a reflux stenosis that was likely to be
verlooked initially. After removal of this island with ER,
his patient continued to have CR-IM status. Another pa-
ient had a 1-mm island 18 months after treatment, located
ear the Z-line, and the island was treated with APC.
Focal IM below the neosquamocolumnar junction was
ound in 3 patients in single biopsy specimens obtained
uring follow-up. This finding was not reproduced in 33
ollow-up biopsy specimens obtained at the neosquamo-
olumnar junction in 6 procedures. Of the 1272 biopsy
pecimens taken from neosquamous epithelium, only 1
iopsy specimen (2 cm proximal to the neosquamocolum-
ar junction) showed focal subsquamous IM without
eoplasia.
DISCUSSION
In this study, 83% of the patients with BE 10 cm
containing early neoplasia were effectively treated with
RFA preceded by ER for visible abnormalities, when pres- d
688 GASTROINTESTINAL ENDOSCOPY Volume 73, No. 4 : 2011nt. The treatment not only resulted in complete removal
f all neoplasia but also complete endoscopic and histo-
ogical removal of the whole BE segments. There were no
evere complications, and, remarkably, these results were
chieved by using an apparently similar number of treat-
ents as are used for BE 10 cm.8-13,15
Our data are in accordance with the reported rates of
omplete remission of neoplasia and IM by Shaheen et
l,13 even though longer BE segments were treated in our
tudy. However, in contrast to the study of Shaheen et al,
ur treatment protocol permitted two instead of one cir-
umferential ablation as well as an escape treatment with
R after the maximum number of RFA treatments in the
ase of residual endoscopic BE. Thus, our study shows
imilar complete remission rates of neoplasia and IM but
ith a more extensive treatment protocol. Compared with
revious RFA studies from our own group in which we
sed the same protocol, the remission rates for BE10 cm
ere lower and did not reach the 95% to 100% complete
emission of neoplasia and IM.9-12,15 This difference in
emission rate was a result of our decision in 4 patients to
iscontinue treatment because of poor healing and no
isible regression in the surface area of BE despite medi-
ation compliance and increased esomeprazole dosage
80 mg twice daily). We hypothesize that this reflects the
everity of the underlying reflux disease in this selected
roup of BE patients. Nevertheless, in the remaining pa-
ients, complete remission of neoplasia and IM was
chieved with a median of 3 RFA treatments, which is
imilar to the 3 to 4 RFA treatments that have been re-
orted for shorter BE segments.9-13,15
During treatment of our patients, we encountered sev-
ral technical challenges that have not been reported in
atients with shorter BE. First, half of the patients were
ound to have a relative reflux stenosis at the upper end of
he BE. In some patients, prior dilatation of this stenosis
as required to allow introduction of ER-caps and RFA
atheters. In addition, reflux stenoses may have led to a
onservative selection of the ablation balloon-catheter di-
meter. In theory, a conservative balloon choice may re-
ult in less contact between the electrode and the mucosa
n the wider distal part of the esophagus, therefore result-
ng in suboptimal treatment. Further difficulties encoun-
ered during RFA treatment of BE 10 cm were nontrans-
ural lacerations that were seen in 27% of patients after
ircumferential ablation, occurring at the reflux stenosis or
revious ER site (ie, the narrowest part of the esophagus).
hese lacerations were, however, asymptomatic and did
ot require intervention. When a laceration was noticed
fter the first pass, further RFA was modified or stopped
uring that session to prevent deeper laceration and fur-
her ablation of the deeper layers. Nevertheless, lacera-
ions did not impede subsequent treatment 2 to 3 months
ater.
Only one patient (4%), who underwent previous ER,
eveloped symptoms of dysphagia after RFA, which
www.giejournal.org
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Herrero et al Endoscopic radiofrequency ablation in Barrett’s esophagusresolved after two dilatations. Dysphagia was rare after
RFA, unlike after other endoscopic treatment modali-
ties, such as radical ER and photodynamic therapy,
which, despite the fact that they are generally applied in
shorter BE, are associated with stenosis in more than
25% of patients.15,18,19
During follow-up, 3 patients were found to have focal
IM below the neosquamocolumnar junction. IM was, how-
ever, found only in a single biopsy specimen during one
follow-up endoscopy, and it was not reproduced during
subsequent follow-up endoscopies. It might be that IM in
this region is a physiological finding, because others have
reported that approximately 25% of the normal population
shows IM in biopsies of the cardia.24,25 On the other hand,
e cannot completely exclude that IM below the neos-
uamocolumnar junction after RFA is a remnant of persist-
ng IM not found previously because of sampling error or
ven being the start of more widespread new-onset IM.
urther follow-up is needed to elucidate the relevance of
M in the neosquamocolumnar junction.
This study has some limitations that need to be ad-
ressed. First, it was performed in tertiary-care referral
enters. Endoscopies were performed by experienced en-
oscopists in the field of BE imaging, and therapy and
athology were reviewed in consensus by expert GI pa-
hologists. Second, the patients in this study were a highly
elected group not frequently seen in common practice.
he results may therefore not be generalized to centers
ith different set-ups. Finally, the follow-up time is rela-
ively short. Longer follow-up is needed to show whether
he complete remission will be sustained in this selected
roup of patients with probably more severe reflux dis-
ase. Nevertheless, previous studies in this field have re-
orted neoplasia recurrence rates of approximately 19% to
0% during a median follow-up of 1.5 to 5 years, with most
f the recurrences developing within the first 15 months
fter treatment.5-7
In our opinion, the treatment of patients with BE 10
cm should be performed in centers with experience in
imaging and therapy of BE. It is not only essential to
recognize all subtle abnormalities that may harbor cancer
in such a long BE, but the treatment itself also is techni-
cally more demanding because of the reflux stenoses and
the ER scars. In addition, the number of patients with no or
poor regeneration of neosquamous epithelium after RFA is
relatively high. Further research is necessary to predict
which patients will not respond adequately to RFA as well
as which mechanisms underlie this lack of response.
In conclusion, RFA of BE segments10 cm seems to be
more challenging: ablations were stopped in 15% of pa-
tients because of poor healing and no regression, which
probably reflects the severity of the reflux disease in this
selected group of patients. Nevertheless, the vast majority
of this complex group of patients with BE reached com-
plete removal of neoplasia and complete reversal of the
BE segment without severe complications and with a sim-
www.giejournal.org Vlar number of treatment sessions as reported for patients
ith shorter BE segments.
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